Hereditary angioedema (HAE) is a rare genetic disorder that causes recurrent episodes of severe swelling in various parts of the body. The swelling is caused by a deficiency or dysfunction of a protein called C1-inhibitor. There is no cure for HAE, but there are treatments that can help to prevent or control attacks. With proper treatment, people with HAE can live normal, active lives. HAE is classified in Type 1, Type 2 and HAE with Normal C1-Inhibitor.
Patients are the experts in their condition and advocacy groups provide a platform for patient voices. Working directly with these communities is the key to pushing research forward in an inclusive way.
We’ve committed to having 500,000 conversations in the next three years, to equip ourselves and our Pharma partners with the insights needed to increase predictability.
The ever-growing investment in advocacy doesn’t appear to be slowing down, and research is certainly seeing the benefits. Which at the end of the day, means better patient care and more options for patients.
We’re ready to keep forming links between our Advocacy friends and Pharma partners, so these fruitful relationships continue to evolve beyond the study-to-study view.
Add your voice to the research conversation
Share My Story